chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 41.0
Sex: F
Vaccine: FLU4, PPV
Symptoms: Vaccination site pain
Clinical narrative: This spontaneous case, initially received on 12-Jan-2017, was reported by a health authority and concerns a(n) 41-year-old female patient. Weight: not provided; Height: not provided. Past medical history included Hypertension, Anxiety. Drug history included Penicillin Concomitant medication: refer to appropriate report section. Administration of company suspect drug(s): The patient received AFLURIA for Indication reported from 27-SEP-2016 to 27-SEP-2016 Dose regimen: 0.5 ml, Site: left arm, Route of administration: Intramuscular, Batch number: 12849211A. Additional suspect drug: The patient received PNEUMOVAX for Indication not reported from 27-SEP-2016 to 27-SEP-2016 Dose regimen: Not reported, Site: right arm, Route of administration: Intramuscular. Batch number: M022552. Adverse reactions/events and outcomes: On 28-Sep-2016, the patient developed inflammation ad pain at the site of vaccination, mild subjective fever with bone pain (9/10). The patient received ibuprofen at 800 mg (1 oral every 6 hours as needed). "QTP 90". She underwent laboratory tests for complete blood count, differential white blood cell count and platelet count. The outcome was recovered. Reporter's comments: The health authority assessed the events as non-serious. Case correction 21-Mar-2017: The lower level (LLT) for the event 'pain at site of vaccination' changed from 'injection site pain' to 'vaccination site pain'. The event 'injection site pain' (outcome: recovered/resolved, start date: 28-Sep-2016) was added. The health authority report the preferred term: injection site pain.
Age: 82.0
Sex: M
Vaccine: FLU4
Symptoms: Muscular weakness, Vaccination site pain
Clinical narrative: This spontaneous case, initially received on 12-Jan-2017, was reported by a health authority and concerns a(n) 82-year-old male patient. Weight: not provided; Height: not provided. Past medical history included HTN, PUD, Fat, CML, Anemia, BPH. Concomitant medication: refer to appropriate report section. Administration of company suspect drug(s): The patient received AFLURIA from 05-OCT-2016 to 05-OCT-2016. Dose regimen: 0.5 ml, site: unknown, Route of administration: Unknown. Batch number: WT55907. No additional suspect drugs. Adverse reactions/events and outcomes: On 25-Oct-2016, the patient had prolonged pain and weakness in shoulder at the site of vaccine. The outcome is not recovered. Reporter's comments: The health authority assessed the events as non-serious. The authority reported event was 'injection site reaction'. Case correction 21-Mar-2017: The lower level (LLT) for the event 'prolonged pain at site of vaccination' changed from 'injection site pain' to 'vaccination site pain'. The event 'injection site pain' (outcome: not recovered / not resolved, start date: 25-Oct-2016) added. The health authority report the preferred term: injection site pain.
Age: 58.0
Sex: F
Vaccine: FLU3, PPV
Symptoms: Limb discomfort, Mobility decreased, Musculoskeletal pain, Pain in extremity
Clinical narrative: This spontaneous case, initially received on 12-Jan-2017, was reported by a health authority and concerns a(n) 58-year-old female patient. Weight: not provided; Height: not provided. Drug history included Sulfa drug. At the time of the event the patient had Asthma. Concomitant medication: refer to appropriate report section. Administration of company suspect drug(s): The patient received AFLURIA for Indication not reported from 07-OCT-2017 to 07-OCT-2017 Dose regimen: 0.5 ml, Site: right arm, Route of administration: unknown. Batch number: WT52205. Non-company suspect drugs: PNEUMOVAX, Indication: Indication not reported, batch number: M0298680, Site: left arm. Adverse reactions/events and outcomes: On 14-Oct-2016, the patient experienced pain all the way down her shoulder to her waist. Her arm felt really heavy (right). She could not raise her arm over her head. She tried paracetamol/ibuprofen but it did not get better. The outcome was not recovered.  Reporter's comments: The health authority assessed the events as non-serious. Case correction 20-Mar-2017: The event 'pain all the way down [her should to her wrist]' (outcome: not recovered/not resolved, start date: 14-Oct-2016) was added and coded to the lower level term (LLT) 'pain in arm'.
Age: 50.0
Sex: F
Vaccine: FLU3
Symptoms: Lethargy, Pruritus, Rash generalised, Syncope, Urticaria
Clinical narrative: This spontaneous case, initially received on 12-Jan-2017, was reported by a health authority and concerns a(n) 50-year-old female patient. Weight: not provided; Height: not provided. Drug history included PCN (penicillin), Amoxicillin, BIAXIN, Tetracycline, Erythromycin Concomitant medication: refer to appropriate report section. Administration of company suspect drug(s): The patient received AFLURIA for Indication not reported form 12-OCT-2016 to 12-OCT-2016 Dose regimen: 0.5 ml, Site: left arm, Route of administration: Unknown, Batch number: 126492221A. No additional suspect drugs. Adverse reactions/events and outcome: On 13-Oct-2016 in the morning, the patient experience fainting spell and felt lethargic all day. On 14-Oct-2016 in the morning, the patient experienced rash/hives over large part of the body and itching. She took diphenhydramine and aluminum hydroxide gel and the rash subsided. Itching was active on 18-Oct-2016 and subsided on 20-Oct-2016. The outcome was recovered. Reporter's comments: The health authority assessed the events as non-serious. Case correction 20-Mar-2017: The lower lever term (LLT) for the event 'rash over large part of body' changed from 'rash' to 'rash generalised'. The event 'rash' (outcome: recovered/resolved, start date: 14-Oct-2016) added and coded to LLT 'rash'.
Age: 39.0
Sex: M
Vaccine: FLU4
Symptoms: Rash
Clinical narrative: This spontaneous case, initially received on 12-Apr-2017 was reported by other non-health professional via regulatory authority (vaccine adverse event reporting system: 669544) and concerns a 39-years-old adult male patient. Administration of Company suspect drug: On 25-Nov-2016, the patient was administered with AFLURIA QUADRIVALENT (Batch number: WT56407) via intramuscular route on right arm for an unknown indication. Adverse reactions/events and outcomes: On 28-Nov-2016 the patient experienced mild to moderate body rash on arms and trunk(Rash) after 3 days of administration of flu shot. It was reported that if the event rash was not improved the patient was suggested to urgent care in town. Action taken with the suspect product was not reported. Outcome of the event rash was not reported. Treatment medications included: On 2-Dec-2016 the patient was instructed to take Diphenhydramine for rash. Reporter's Assessment: The reporter assessed the event as non-serious and the causality for the event rash was not Reported. This case is non-serious.
Age: 53.0
Sex: F
Vaccine: FLU4, PNC13
Symptoms: Injection site erythema, Injection site inflammation, Injection site urticaria
Clinical narrative: This Spontaneous case, initially received via Vaccine adverse event reporting systems (VAERS ID: 671127) on 12-Apr-2017, was reported by other non-healthcare professional and concerns a 53-year-old female patient. At the time of the event the patient had Hypertension, Plasma cell myeloma. The patient's concomitant medication included: Levothyroxine, Amlodipine Besylate, Simvastatin, BANOPHEN, Dologesic and Indapamide. Administration of Company suspect drug: On 05-Dec-2016, the patient administered with AFLURIA QUADRIVALENT (dose: 0.5ml, batch number:16700001, route of administration: intramuscular and anatomical location: right arm). Non-company suspect drug: On 05-Dec-2016, the patient administered with PREVNAR 13 (dose: not reported, batch number: N97935, route of administration: intramuscular and anatomical location: left arm). Indication was not reported. Adverse reactions/events and outcomes: On 06-Dec-2016 after administration of AFLURIA QUADRIVALENT, the patient experienced Moderate to severe urticaria (Injection site urticaria), patient presented with inflamed site of immunisation and patient presented redness at site of immunisation. Treatment medications: Diphenhydramine 50 mg was given to manage the injection site erythema, injection site urticaria and injection site inflammation. Action taken with the AFLURIA QUADRIVALENT was not reported. The outcome of the events were not reported. Reporter's Assessment: The reporter did not provide the causality between AFLURIA QUADRIVALENT and events. This report was non-serious.
Age: 30.0
Sex: M
Vaccine: FLU4
Symptoms: Pyrexia
Clinical narrative: This Spontaneous case, initially received via VAERS (VAERS ID-674056) on 12-Apr-2017, was reported by other non-health professional and concerns a 30-year-old adult male patient. Administration of Company suspect drug (s): On 08-Dec-2016 the patient was administered by AFLURIA QUADRIVALENT (route of administration, dose, expiration date, batch number: not reported). Adverse events/reactions and outcomes: On 09-Dec-2016 after administration of AFLURIA QUADRIVALENT, the patient experienced fever (pyrexia). The action taken with AFLURIA QUADRIVALENT was not reported. The outcome of the event was recovered/resolved. Reporter's Assessment: The reporter did not provide causality between AFLURIA QUADRIVALENT and event. This case report was non-serious.
Age: 29.0
Sex: F
Vaccine: FLU4
Symptoms: Headache
Clinical narrative: This spontaneous case, initially received on 12-Apr-2017 was reported by other non-health professional via health authority (VAERS ID: 676067) and concerns 29 years old female adult patient. The patient's medical history included spring hay fever. Administration of Company suspect drug: On 09-Nov-2016, the patient received AFLURIA QUADRIVALENT (dose: 1 DF, dose: 0.5 ml, expiry date, batch number: not reported) at left arm. Adverse reactions/events and outcomes: On 19-Nov-2016, after administration of the influenza vaccine (flu shot) the patient experienced headache on a regular basis at least every other day. The reporter stated that the OTCs (over the counter drugs) was useless in treating the pain and migraine medications was not recommended by the PCP (primary care physician). Action taken with the suspect vaccine was not reported. The outcome of the event was not recovered. Reporter's Assessment: The reporter did not provided the causality of the event in relation to the AFLURIA QUADRIVALENT. Health authority considered the case as non-serious.
Age: 28.0
Sex: F
Vaccine: FLU4
Symptoms: Injection site erythema, Injection site pain, Injection site swelling, Nausea
Clinical narrative: This spontaneous case, initially received via Vaccine adverse event reaction systems (VAERS ID: 676873) on 12-Apr-2017 was reported by other non-healthcare professional and concerns a 28 years female patient. Administration of Company suspect drug (s): On 02-Jan-2017, the patient received intramuscular AFLURIA QUADRIVALENT of 1 DF (0.5 ml) and batch number: WT53206 on left arm. Adverse reactions/events and outcomes: On 02-Jan-2017 after administration of AFLURIA QUADRIVALENT, the patient experienced redness (injection site erythema), soreness (injection site pain), swelling (injection site swelling) and nausea for more than 3 days. Action taken with AFLURIA QUADRIVALENT was not reported. The events were recovered. Reporter's Assessment: The reported assessed the events as non-serious and the causality was not reported. This report was not serious.
Sex: M
Vaccine: FLU4, IPV, TDAP
Symptoms: Pyrexia, Vomiting, Withdrawal syndrome
Clinical narrative: This spontaneous case, initially received on 12-APR-2017, was reported by other non-health professional via regulatory authority (VAERS ID: 677532) and concerns a 28-years-old male patient. The patient's medical history included: obesity, seizures, loss of consciousness, tremors, chills and ETOH detox. The patient was allergic to kiwi fruit, beets and had a history of polysubstance abuse. The patient's concomitant medication included: ZOFRAN. Administration of company suspect drug: On 09-Jan-2017, the patient was administered with AFLURIA QUADRIVALENT (dosage: 0.5 ml, batch number: WT58208, route of administration: intramuscular and anatomical location: right arm). Non-company suspect drug: On 09-Jan-2017, the patient was administered with TDAP IPV (dosage: not reported, batch number: U5459AB, route of administration: intramuscular and anatomical location: left arm). Adverse reactions/events and outcomes: On 09-Jan-2017, after administration of the vaccine, the patient had fever of 102.2 and vomiting. On 08-Jan-2017, patient was admitted to health care systems for detox with a bac 0. On 09-Jan-2017 at 15:11, the patient received ZOFRAN. The patient was vomiting actively and gone through withdrawals. The action taken with the influenza vaccine was not reported. The outcome of the events was recovered. Reporter's Assessment: The reporter did not provide the causality between influenza vaccine and events. This case report was not serious.
Sex: M
Vaccine: FLU4
Symptoms: Injection site swelling
Clinical narrative: This spontaneous case, initially received via VAERS (ID: 677873) on 12-Apr-2017, was reported by an other non-health professional and concerns a 70 years old male adult patient. Administration of Company suspect drug (s): On 12-Jan-2017, the patient received intramuscular AFLURIA QUADRIVALENT (dose: 0.5 ml, batch number:14049222A). Adverse reactions/events and outcomes: On 12-Jan-2017 after administration of influenza vaccine, the patient experienced swelling at injection site. As a treatment, ice was applied and swelling diminished after 10 minutes. Action taken with influenza vaccine was not reported. The outcome of the event was reported as recovered on 12-Jan-2017. Reporter's Assessment: The reporter did not providedthe causality between influenza vaccine and the event. This report was not serious.
Age: 31.0
Sex: F
Vaccine: FLU4
Symptoms: Rash
Clinical narrative: This spontaneous case, initially received on 12-Apr-2017 was reported by other non-health professional via regulatory authority (vaccine adverse event reporting system: 679359) and concerns a 31-years-old elderly female patient. Administration of Company suspect drug: On 19-Jan-2016, the patient was administered with AFLURIA Quadrivalent (Batch number: 13949211A) via intramuscular route on right arm. Adverse reactions/events and outcomes: It was reported that, on 19-Jan-2017 few hours after receiving the influenza vaccine the patient experienced a mild rash. The rash did not last more than a couple of hours. The patient does no experience any other symptoms. Action taken with the influenza vaccine was not reported. Outcome of the event rash was recovered. Reporter's Assessment: The reporter did not provide the causality between the influenza vaccine and event rash. This case was not serious.
Age: 20.0
Sex: F
Vaccine: FLU3
Symptoms: Injection site pain, Pain in extremity, Skin discolouration
Clinical narrative: This spontaneous case, reported by Other Health Professional to VAERS and initially retrieved on 05-Mar-2018 by Seqirus from VAERS (VAERS ID: 689223) concerns a 20-year-old female patient. The patient had no medical history. The patient's concomitant medication included Bisoprolol/HCTZ. On 05-Aug-2016, the patient was administered with AFLURIA QUADRIVALENT (dose: 0.5ml, route of administration: not reported, anatomical location: right arm, batch number: WT51805). On the same day, after vaccine administration the patient had a mark on the arm and pain. It was reported that, the mark was still present to that day and had consistent arm pain at the injection site. At time of this report, the patient had not yet recovered from the events. The reporter assessed the case as non-serious.
Sex: F
Vaccine: FLU3, HEP, IPV, MNQ, TDAP
Symptoms: Feeling hot, Heart rate increased, Injection site swelling
Clinical narrative: This spontaneous case, reported by health care professional (other) to VAERS and initially retrieved on 05-Mar-2018 by Seqirus from VAERS (VAERS ID: 689753), concerns a 20-year-old, adult, female patient. The patient's medical history and concomitant medications were not reported. On 06-Apr-2017, the patient was administered with AFLURIA (dose: 0.5 ml, route of administration: intramuscular, anatomical location: left arm, batch number: 13549211A (1359211A as reported) and expiry date: not reported). On the same day, the patient was administered with non-company suspect product, ENGERIX B (dose, route of administration: intramuscular, anatomical location: right arm, batch number: B23 (as reported) and expiry date: not reported), MENACTRA (dose, route of administration: intramuscular, anatomical location: right arm, batch number: U5523BA (as reported) and expiry date: not reported), IPOL polio vaccine (dose, route of administration: intramuscular, anatomical location: left arm, batch number: N1F181M (as reported) and expiry date: not reported) and BOOSTRIX (dose, route of administration: intramuscular, anatomical location: left arm, batch number: 3457Y (as reported) and expiry date: not reported). On an unspecified date, the patient experienced local swelling of left arm at injection site, elevated heart rate. The patient also felt hot. After 30 minutes, the swelling went down along with heart rate. At the time of report, the patient had recovered from the events (feeling hot, heart rate increased and swelling of injection site). The reporter assessed the case as non-serious.
Sex: U
Vaccine: FLU3
Symptoms: Contraindication to vaccination
Clinical narrative: This spontaneous case, reported by other healthcare professional to VAERS and initially retrieved on 05-Mar-2018 by Seqirus from VAERS (VAERS ID: 690306), concerns a 13-month-old infant patient of an unspecified gender. The patient's medical history and concomitant medications were not reported. The patient had been allergic to egg. On 09-Jan-2017, the patient was administered with AFLURIA TIV (dose: 0.5 ml, route of administration, anatomical location, batch number and expiry date: not reported). It was stated that, the patient was kept in clinic for 20 minutes and heart rate, pulse rate were monitored for which results were not reported. The patient's mother was instructed to given BENADRYL, if needed at home. At the time of this report, the outcome of the event was not reported. The reporter assessed the event as non-serious.
Age: 45.0
Sex: F
Vaccine: FLU4
Symptoms: Hypoaesthesia, Loss of personal independence in daily activities, Musculoskeletal disorder, Pain in extremity, Sleep disorder
Clinical narrative: This is a spontaneous case, reported by other healthcare professional to VAERS and initially retrieved on 05-Mar-2018 by Seqirus from VAERS (VAERS ID: 690749), concerns a 45-year-old adult female patient. The patient's historical condition included lymphedema of LLE (left lower extremity). The patient had no current conditions. The patient's concomitant medications included Aspirin, Flax seed, zinc, calcium/magnesium and cranberry. On 28-Oct-2016, the patient was administered with AFLURIA (dose: 0.5 ml, route of administration: intramuscular, anatomical location: left arm, batch number: WT57208 and expiry date: not reported). On the same day, after the vaccination, the patient had chronic arm pain, numbness in hand, limited use of arm and hand. The patient also experienced sleep disturbance and activity of daily living impaired. At the time of this report, the patient had not yet recovered from the events. The reporter assessed the events as non-serious. Non-significant case correction received 05-Mar-2018: The narrative was corrected from "patient also experienced interfere with daily activities and sleep" to "patient experienced sleep disturbance and activity of daily living impaired".
Sex: F
Vaccine: FLU3
Symptoms: Radioallergosorbent test negative, Rash erythematous, Skin reaction
Clinical narrative: This spontaneous case, reported by other health professional to VAERS and initially retrieved on 14-Mar-2018 by Seqirus from VAERS (VAERS ID: 691769), concerning a 27-year-old, adult female patient. The patient's historical condition included: G6PD (Glucose-6-phosphate dehydrogenase) deficiency anemia. The patient did not have any other current illness and was not using any medications at the time of vaccination. It was reported that when the patient was 10 years of age she had issues where her chest broke out in hives and her face swelled for 2-3 hours but resolved on its own. However, she did not require any medical intervention. On 30-Sep-2017, the patient was administered with AFLURIA (TIV) (dose: 0.5 ml, route of administration: intramuscular, batch number: 11249221A, anatomical location, expiry date: not reported). It was reported that, the patient did not eat eggs or items made with eggs until two years. However, the patient ate mayo/egg breakfast and had similar symptoms on 30-Sep-2015. The patient's family assumed that it was the egg allergy. She has never been officially tested for egg allergy. On the same day, the patient was not aware of the reaction until she mentioned a skin reaction following flu vaccine. Following the flu vaccine, she experienced upper chest (above breasts) broke out in fine red dots 1 hour after flu vaccine. Those symptoms lasted for about 2-3 hours and later it was self-resolved. On 07-Feb-2017, the patient had radio-allergosorbent test (RAST) test IGE to egg white, yolk, porcine/bovine gelatin and esophagitis panel which were found to be negative. On the same day, the patient was administered with FLUBLOK and was referred to clinic for reported egg allergy. The patient had recovered from all the events. The reporter assessed the case as non-serious.
Age: 27.0
Sex: F
Vaccine: FLU3
Symptoms: Pain in extremity
Clinical narrative: This is a spontaneous case, reported by healthcare professional (other) to VAERS and initially retrieved on 05-Mar-2018 by Seqirus from VAERS (VAERS ID: 692041), concerns a 27-year-old, adult, female patient. The patient's historical condition included asthma (unspecified date). On 27-Oct-2016, the patient was administered with AFLURIA (dose: 0.5 ml, route of administration: intramuscular, anatomical location: left arm, batch number: WT53406 (reported as WTS3406) and expiry date: not reported). On the same day, after the vaccination, the patient experienced pain in deltoid area. As of 25-Apr-2017, the patient had not yet recovered from the event. The reporter assessed the event as non-serious.
Age: 22.0
Sex: F
Vaccine: FLU4, PPV
Symptoms: Injection site pain
Clinical narrative: This spontaneous case, reported by other health professional to VAERS and initially retrieved on 05-Mar-2018 by Seqirus from VAERS (VAERS ID: 692247), concerning a 22-year-old, adult female patient. The patient's current conditions included: asthma and acute respiratory infection (since unspecified dates). Concomitant medications included: ADVAIR, LEXAPRO and FLONASE. On 06-Apr-2017, the patient was administered with AFLURIA (dose: 0.5 ml, route of administration: injection (reported as SYR), anatomical location: left arm, batch number: WT53406, expiry date: not reported). On the same day, the patient was administered with PNEUMOVAX (dose: 1 DF, route of administration: injection (reported as SYR), anatomical location: left arm, batch number: M037533, expiry date: not reported). On the same day, after hours of receiving flu and PNEUMOVAX, the patient reported 8/10 pain at injection site. She was treated with TYLENOL on the same day late evening. She also applied ice pack and continued TYLENOL for pain. Later, she visited emergency room/physician visit for evaluation. The patient had recovered from the event injection site pain. The reporter assessed the event as non-serious.
Age: 71.0
Sex: M
Vaccine: FLU3
Symptoms: Rash
Clinical narrative: This non-serious initial spontaneous case, was received from other non-health professional via health authority (VAERS Id: 693659) on 21-Jul-2017, concerning a 71-year-old male patient. The patient had no current illness and medical history. On 20-Jan-2017, the patient was administered with AFLURIA (dose: 0.5 (reported as: 1), anatomical location: left arm, batch number: WT57908, expiry date, route of administration not reported). On 21-Jan-2017, after the vaccination, the patient developed rash. The outcome of the event was recovered.
Age: 18.0
Sex: M
Vaccine: FLU3
Symptoms: Malaise, Pharyngeal oedema, Throat irritation
Clinical narrative: This initial spontaneous case, received on 05-Dec-2017, reported by other health professional via regulatory authority (VAERS ID: 701267) and concerns an 18-year-old adult male patient. It was reported that, the patient was allergic to amoxicillin A. On 30-Jun-2017, the patient received AFLURIA (dose: not reported, route of administration: intramuscular, anatomical location: right arm, batch number: WT58908). On an unspecified date, the patient received hepatitis B vaccine (dose: not reported, route of administration: intramuscular, anatomical location: left arm, batch number: 9Z924). On an unspecified date, the patient received MENACTRA (dose: not reported, route of administration: intramuscular, anatomical location: left arm, batch number: U5556BA). On an unspecified date, the patient received BOOSTRIX (dose: not reported, route of administration: intramuscular, anatomical location: right arm, batch number: X994C). On 30-Jun-2017, after administration of the suspect vaccine, the patient did not feel well and had itchy throat. Nasopharyngeal test noted a moderate swelling in throat. The subject was treated with BENADRYL and EPIPEN. The patient was sent to HCC (as reported). Upon general examination, no current illness was reported. The outcome of the events was not reported. The reporter assessed the case as non-serious.
Age: 40.0
Sex: M
Vaccine: FLU3, PPV, TDAP
Symptoms: Cellulitis
Clinical narrative: This initial serious spontaneous case, received on 05-Dec-2017, was reported by other health professional (via regulatory authority VAERS ID: 706515) and concerns 40-year-old male patient. The patient's historical conditions included hypertension, hyperlipidemia, alcohol abuse, MDD (major depressive disorder), PTSD (post-traumatic stress disorder), BPH (benign prostatic hyperplasia) and GERD (Gastroesophageal reflux disease). The patient had no history of allergies. The patient was not ill at the time of vaccination. On 15-May-2017, the patient received AFLURIA Thiomersal (dose: 0.5ml (2 as reported), batch number: 13749211B, anatomical location: right arm, route of administration, expiry date: not reported). On the same day, the patient received co-suspect PNEUMOVAX (batch number: N005096, dose: 2 as reported, anatomical location: right arm, route of administration, expiry date: not reported). On the same day, the patient received co-suspect BOOSTRIX (BOOSTRIX/ADACEL) (batch number: ZN937, dose: 2 as reported, anatomical location: right leg, route of administration, expiry date: not reported). On 18-May-2017, 4 days after vaccination, the patient had cellulitis. The patient was treated  with Amoxi-Clav (Amoxicillin/Clavulanate as reported) (550/125 mg, bid). No lab tests were done. The patient recovered from the event on an unspecified date.
Age: 50.0
Sex: F
Vaccine: FLU3
Symptoms: Hypoaesthesia
Clinical narrative: This is a spontaneous case, reported by other healthcare professional to VAERS and initially retrieved on 06-Mar-2018 by Seqirus from VAERS (VAERS ID: 709287), concerns a 50-year-old, adult, female patient. The patient's medical history, allergy and concomitant medication were not reported. On 18-Aug-2017, the patient was administered with AFLURIA (dose: 0.5 ml, route of administration: intramuscular, anatomical location, left arm, batch number: XT59505 and expiry date: not reported). On 19-Aug-2017, after 1 day of vaccination, the patient experienced numbness in left leg and went to the physician office. At the time of this report, the outcome of the event was not reported. The reporter assessed the event as non-serious.   On 19-Aug-2017, after 1 day of vaccination, the patient experienced numbness in left leg and went to the physician office. At the time of this report, the outcome of the event was not reported. The reporter assessed the event as non-serious.
Sex: M
Vaccine: FLUA3, PNC13
Symptoms: Cough, Influenza, Pneumonia, Productive cough
Clinical narrative: This serious spontaneous case, reported by health care professional (other) to VAERS and initially retrieved on 06-Mar-2018 by Seqirus from VAERS (VAERS ID: 710186), concerns a 74-year-old, elderly male patient. The patient had no known allergies and no current illness. The patient's concomitant medications included ZEGERID, amitriptyline, metoprolol, allopurinol, niacin and simvastatin. On 17-Aug-2017, the patient was administered with FLUAD (TIV) (dose: 0.5 ml, route of administration: intramuscular, anatomical location: left arm, batch number: 178503, expiry date: not reported). On the same day, the patient was also administered with PREVNAR 13 (route of administration: intramuscular, anatomical location: left arm, batch number: R75238, dose, expiry date: not reported). On the same day after vaccination, the patient had flu and pneumonia. On 18-Aug-2017, the patient had phlegm and on the next day, he had cough. On 24-Aug-2017, the patient went to primary care physician (PCP) and was treated with antibiotics and unspecified over the counter drugs (OTC). Physician considered it as possible bronchitis. At the time of this report, the outcome of the events was unknown.
Age: 53.0
Sex: F
Vaccine: FLU3
Symptoms: Eyelid oedema
Clinical narrative: This initial spontaneous case, was received from other health professional via health authority (VAERS ID: 711590) on 05-Dec-2017, concerning a 53-year-old adult female patient. On 25-Aug-2017, the patient was administered with AFLURIA (dose: 0.5 ml, route of administration: intramuscular, batch number: XT59706 and anatomical location: not reported). On 27-Aug-2017, after 2 days of vaccination, the patient had swelling under eyes. The patient recovered from the event. The reporter assessed the event as non-serious.
Age: 24.0
Sex: F
Vaccine: FLUX, FLU4, FLU4
Symptoms: Malaise, Myalgia
Clinical narrative: This non-serious case, reported by other non-health care professional to VAERS and initially retrieved, on 21-Feb-2018 by Seqirus from VAERS (VAERS ID: 712377), concerns a 24-year-old, adult, female patient. The patient's current conditions included asthma, ADHD (attention deficit/hyperactivity disorder) and allergic to walnuts, cats, sulfa drugs (causes rash) (since an unspecified dates). On an unspecified date in 2016, the patient was administered with influenza vaccine (dose, route of administration, anatomical location, batch number and expiry date: not reported). On an unspecified date, the patient had malaise and myalgia. At the time of the report, the outcome of the events (malaise and myalgia) were not reported.
Age: 24.0
Sex: F
Vaccine: FLUX, FLU4, FLU4
Symptoms: Asthenia, Asthma, Chest discomfort, Chills, Condition aggravated
Clinical narrative: This non-serious case, reported by other non-health care professional to VAERS and initially retrieved, on 21-Feb-2018 by Seqirus from VAERS (VAERS ID: 712377), concerns a 24-year-old, adult, female patient. The patient's current conditions included asthma, ADHD (attention deficit/hyperactivity disorder) and allergic to walnuts, cats, sulfa drugs (causes rash) (since an unspecified dates). On an unspecified date in 2016, the patient was administered with influenza vaccine (dose, route of administration, anatomical location, batch number and expiry date: not reported). On an unspecified date, the patient had malaise and myalgia. At the time of the report, the outcome of the events (malaise and myalgia) were not reported.
Age: 24.0
Sex: F
Vaccine: FLUX, FLU4, FLU4
Symptoms: Discomfort, Dyspnoea, Headache, Heart rate increased, Hyperhidrosis
Clinical narrative: This non-serious case, reported by other non-health care professional to VAERS and initially retrieved, on 21-Feb-2018 by Seqirus from VAERS (VAERS ID: 712377), concerns a 24-year-old, adult, female patient. The patient's current conditions included asthma, ADHD (attention deficit/hyperactivity disorder) and allergic to walnuts, cats, sulfa drugs (causes rash) (since an unspecified dates). On an unspecified date in 2016, the patient was administered with influenza vaccine (dose, route of administration, anatomical location, batch number and expiry date: not reported). On an unspecified date, the patient had malaise and myalgia. At the time of the report, the outcome of the events (malaise and myalgia) were not reported.
Age: 24.0
Sex: F
Vaccine: FLUX, FLU4, FLU4
Symptoms: Malaise, Muscle spasms, Myalgia, Nausea, Pain
Clinical narrative: This non-serious case, reported by other non-health care professional to VAERS and initially retrieved, on 21-Feb-2018 by Seqirus from VAERS (VAERS ID: 712377), concerns a 24-year-old, adult, female patient. The patient's current conditions included asthma, ADHD (attention deficit/hyperactivity disorder) and allergic to walnuts, cats, sulfa drugs (causes rash) (since an unspecified dates). On an unspecified date in 2016, the patient was administered with influenza vaccine (dose, route of administration, anatomical location, batch number and expiry date: not reported). On an unspecified date, the patient had malaise and myalgia. At the time of the report, the outcome of the events (malaise and myalgia) were not reported.
Age: 24.0
Sex: F
Vaccine: FLUX, FLU4, FLU4
Symptoms: Pyrexia
Clinical narrative: This non-serious case, reported by other non-health care professional to VAERS and initially retrieved, on 21-Feb-2018 by Seqirus from VAERS (VAERS ID: 712377), concerns a 24-year-old, adult, female patient. The patient's current conditions included asthma, ADHD (attention deficit/hyperactivity disorder) and allergic to walnuts, cats, sulfa drugs (causes rash) (since an unspecified dates). On an unspecified date in 2016, the patient was administered with influenza vaccine (dose, route of administration, anatomical location, batch number and expiry date: not reported). On an unspecified date, the patient had malaise and myalgia. At the time of the report, the outcome of the events (malaise and myalgia) were not reported.
Age: 68.0
Sex: F
Vaccine: FLUA3, PPV
Symptoms: Cellulitis, Erythema, Pain in extremity, Peripheral swelling
Clinical narrative: This spontaneous case, reported by other non-healthcare professional to VAERS and initially retrieved on 06-Mar-2018 by Seqirus from VAERS (VAERS ID: 713667), concerns a 68-year-old, elderly female patient. The patient had no known allergies and current illness. The concomitant medications included ZYRTEC-D, FLONASE, lisinopril, atorvastatin for unknown indications. On 12-Sep-2017, the patient was administered with FLUAD (TIV) (dose: 0.5 ml (reported as 1 DF), route of administration: intramuscular, anatomical location: left arm, batch number: 179001, expiry date: not reported) and PNEUMOVAX (dose: 1 DF, route of administration: intramuscular, anatomical location: right arm, batch number: N013541, expiry date: not reported). On the same day in the evening, after administration of vaccine, the patient experienced pain and swelling in the right arm. On 13-Sep-2017 (next day morning), the arm appeared red, was swollen and painful (specified as not at site of injection but area below and above elbow). On 14-Sep-2017, the patient was taken to the urgent care for consultation. Due to lack of facility to test, the patient was taken to the emergency care and was admitted. The patient was diagnosed with cellulitis and was treated with unspecified medications. The patient recovered from cellulitis. On 23-Sep-2017 (Saturday afternoon), the patient was discharged from the hospital. At the time of the discharge, the patient was prescribed with doxycycline and cephalexin. At the time of report, the patient recovered from the events. The reporter assessed the case as serious due to hospitalization. Case correction received 06-Mar-2018: The 'as determined causality' for all the events were changed from related to not related. Case comment was amended accordingly.
Sex: F
Vaccine: FLUX
Symptoms: Injection site erythema
Clinical narrative: This is a spontaneous case, reported by other healthcare professional to VAERS and initially retrieved on 06-Mar-2018 by Seqirus from VAERS (VAERS ID: 714699), concerns a female patient of an unspecified age. On an unspecified date, the patient was administered with influenza vaccine (dose, route of administration, anatomical location, batch number and expiry date: not reported). On an unspecified date, after the vaccination, the patient developed redness at injection site, which was not more red and large. At the time of this report, the outcome of the event was not reported. The reporter assessed the events as non-serious.   On an unspecified date, after the vaccination, the patient developed redness at injection site, which was not more red and large. At the time of this report, the outcome of the event was not reported. The reporter assessed the events as non-serious.
Age: 24.0
Sex: F
Vaccine: FLU3
Symptoms: Dizziness, Headache, Hypotension, Nausea, Somnolence
Clinical narrative: This initial serious spontaneous case, received on 05-Dec-2017, was reported by other health professional via health authority (VAERS: 715208) and concerns a 24-year-old adult female patient. The patient's current condition included Seizures. The patient's historical drug included DEPAKOTE; DILANTIN and Phenobarb. The patient's concomitant medications included: Vitamin E, Vitamin D, Vitamin B, LAMICTAL; KEPPRA, Zonisamide. On 26-Sep-2017, the patient was administered with AFLURIA (dose: 0.5ml, route of administration: intramuscular, anatomical location: left arm, batch number: XT59606, expiry date: not reported). On 27-Sep-2017, 2 days after the vaccination, the patient started feeling nausea, headache, low blood pressure, sleepiness and dizziness. The patient was treated with Promethazine for nausea. At the time of this report, the outcome of the event was not reported.
Sex: F
Vaccine: FLU4, PPV
Symptoms: Injection site pain
Clinical narrative: This initial spontaneous case, was received from other health professional via health authority (VAERS ID: 715656) on 05-Dec-2017, concerning a 51-year-old adult female patient. On 13-Sep-2017, the patient was administered with AFLURIA QUADRIVALENT (dose: 0.5ml, route of administration: intramuscular, anatomical location: right arm, batch number XF3008 and expiry date: not reported). On the same day, the patient was administered with PNEUMOVAX (route of administration: intramuscular, anatomical location: right arm, batch number: N013541 (as reported) and expiry date: not reported). On 19-Sep-2017, after 7 days of vaccination, the patient experienced pain and soreness at the injection site. The patient was treated with antibiotics (unspecified). The reporter assessed events as non-serious.
Age: 60.0
Sex: F
Vaccine: FLU4
Symptoms: Injection site pain
Clinical narrative: This initial spontaneous case, was received from other health professional via health authority (VAERS ID: 715659) on 05-Dec-2017, concerning a 60-year-old adult female patient. The patient's medical history and concomitant medications were not reported. On 13-Sep-2017, the patient was administered with AFLURIA QUADRIVALENT (dose: 0.5 ml (reported as 1), route of administration: intramuscular, anatomical location: right arm, batch number: XF33008 and expiry date: not reported). On 19-Sep-2017, after 6 days of vaccination, the patient had pain and soreness at injection site. The patient visited the physician office and was given antibiotics (unspecified). The outcome of the event was reported as recovered. The reporter assessed the events as non-serious.
Age: 55.0
Sex: M
Vaccine: FLU4
Symptoms: Pruritus, Urticaria
Clinical narrative: This initially spontaneous case was received on 05-Dec-2017 from the other health professional via regulatory authority (VAERS ID: 715722), concerns a 55-year-old adult male patient. The patient had seasonal environmental allergies (grass pollen, ragweed etc.). The patient's concomitant medication included Lisinopril, Vitamin C, Multivitamins. On 23-Sep-2017, the patient was administered with AFLURIA QUADRIVALENT (dose: 0.5ml, anatomical location: right arm, route of administration, batch number, expiry date: not reported). On the same day, after vaccine administration, the patient had itching sensation (hives) in upper and lower extremities. At the time of this report, the patient was recovered from the events. The reporter assessed the events as non-serious.
Age: 18.0
Sex: F
Vaccine: FLUX
Symptoms: Dizziness, Facial pain, Musculoskeletal pain, Nausea, Vomiting
Clinical narrative: This is spontaneous case, reported by other non-healthcare professional to VAERS and initially retrieved on 03-Feb-2018 by Seqirus from VAERS (VAERS ID: 716422), concerning an 18-year-old, adult, female patient. The patient's medical history was not reported. Concomitant medication included: CETRINE for an unknown indication. On 02-Oct-2017, the patient was administered with influenza vaccine, (dose: 1 (as reported), route of administration: injection (reported as SYR), anatomical location: left arm, batch number, expiry date, trade name, manufacturer: not reported). On the same day (02-Oct-2017), after few hours of vaccination, the patient experienced nausea, her face was hurting on the cheeks and temples. In addition, she had shoulder pain and was very light headed. Hence, she laid down. When the patient woke up after half an hour, she felt thrown up. Hence, she laid down again, but probably for a few hours. Subsequently, when she woke up, her face was not much sore, but she still felt nauseous and had thrown up bile. The patient had recovered from the events (pain in face, shoulder pain, light headedness, nausea and vomiting). The reporter considered this case as non-serious.
Age: 56.0
Sex: F
Vaccine: FLU4
Symptoms: Rash, Rash erythematous, Rash pruritic
Clinical narrative: This initial spontaneous case, was received from other health professional via health authority (VAERS ID: 716626) on 05-Dec-2017, concerning a 56-year-old adult female patient. The patient's medical history included hypertension (unspecified date). The patient had no current illness, allergies and she did not receive any concomitant medications. On 03-Oct-2017, the patient was administered with AFLURIA QUADRIVALENT (dose: 0.5 ml, route of administration, anatomical location, batch number and expiry date: not reported). On 04-Oct-2017, after 1 day of vaccination, the patient developed itchy and red rash on front and back of torso. At the time of this report, the patient had not yet recovered from the events. The reporter assessed the case as non-serious.
Sex: F
Vaccine: FLU3
Symptoms: Dizziness, Ear, nose and throat examination, Headache, Ophthalmological examination, Vaccination complication
Clinical narrative: This initial spontaneous case, was received from other non-health professional via health authority (VAERS ID: 716687) on 05-Dec-2017, concerning a 54-year-old adult female patient. The patient had no medical history. The patient had latex allergy. The patient concomitant medications included atorvastatin, KLOR-CON, Losartan, hydrochlorothiazide for an unknown indication. On 04-Oct-2017, the patient was administered with AFLURIA QUADRIVALENT (dose: 0.5 ml, route of administration: SYR (as reported), anatomical location: left arm, batch number: XT32408 and expiry date: not reported). On the same day, the patient experienced headache, dizziness, blurred vision and did not received any treatment medication. The patient was checked by the nurse at work and her symptoms did not change. Her ears, nose, throat were checked and vision test was done (results not provided). The patient went to outpatient clinic and it was told that, it was reaction to the flu shot. At the time of the report, the patient recovered from the events. The reporter assessed the case as non-serious.
Sex: F
Vaccine: FLU3
Symptoms: Vision blurred
Clinical narrative: This initial spontaneous case, was received from other non-health professional via health authority (VAERS ID: 716687) on 05-Dec-2017, concerning a 54-year-old adult female patient. The patient had no medical history. The patient had latex allergy. The patient concomitant medications included atorvastatin, KLOR-CON, Losartan, hydrochlorothiazide for an unknown indication. On 04-Oct-2017, the patient was administered with AFLURIA QUADRIVALENT (dose: 0.5 ml, route of administration: SYR (as reported), anatomical location: left arm, batch number: XT32408 and expiry date: not reported). On the same day, the patient experienced headache, dizziness, blurred vision and did not received any treatment medication. The patient was checked by the nurse at work and her symptoms did not change. Her ears, nose, throat were checked and vision test was done (results not provided). The patient went to outpatient clinic and it was told that, it was reaction to the flu shot. At the time of the report, the patient recovered from the events. The reporter assessed the case as non-serious.
Age: 74.0
Sex: F
Vaccine: FLUA3, PPV
Symptoms: Pain in extremity
Clinical narrative: This spontaneous case, reported by other healthcare professional to VAERS and initially retrieved on 20-Mar-2018 by Seqirus from VAERS (VAERS ID: 719919), concerns a 74-year-old, elderly female patient. The patient had no relevant medical history, but was allergic to nabumetone. On 02-Oct-2017, the patient was administered with FLUAD (dose: 0.5 ml (reported as 2), route of administration: intramuscular, anatomical location: left arm, batch number: 178623, expiry date: not reported) and PNEUMOVAX (dose: 1 dose (as reported), route of administration: intramuscular, anatomical location: right arm, batch number: N020501, expiry date: not reported). On the same day evening, the patient developed pain in entire arm and visited the emergency room. On an unspecified date, the patient had recovered from the event. The reporter assessed the case as non-serious.
Age: 77.0
Sex: M
Vaccine: FLUA3
Symptoms: Myalgia, Vomiting
Clinical narrative: This spontaneous case, reported by health care professional (other) to VAERS and initially retrieved on 20-Mar-2018 by Seqirus from VAERS (VAERS ID: 720039), concerns a 77-year-old, elderly, male patient. The patient's current condition included high blood pressure (from an unspecified date) and had no allergies. The patient's concomitant medication included vitamins for an unknown indication (on an unspecified date). On 11-Oct-2017 the patient was administered with FLUAD (TIV) (dose: 0.5 ml (1 as reported), route of administration: intramuscular, anatomical location: left arm, batch number: 179303 and expiry date: not reported). On 12-Oct-2017, after 1 day of vaccination, patient experienced severe muscle ache and vomiting. It was reported that, the patient was admitted to emergency department for 1 day. At the time of report, the patient had recovered from the events (vomiting and muscle ache). The reporter assessed the case as serious (hospitalization).
Age: 8.0
Sex: F
Vaccine: FLU4
Symptoms: Injection site rash, Injection site swelling
Clinical narrative: This spontaneous case, reported by other health professional to VAERS and initially retrieved on 21-Feb-2018 by Seqirus from VAERS (VAERS ID: 720333), concerning a 08-year-old, female child. The patient had no medical history, current illness and was not taking any concomitant medications. On 14-Oct-2017, the patient received ALFURIA QUADRIVALENT (dose: 0.5 ml, route of administration: intramuscular, anatomical location: left arm, batch number, expiry date: not reported). On the same day after vaccination, the patient developed rash and swelling at the injection site (without adenopathy). At the time of this report, the patient had not yet recovered from the events (rash and swelling at the injection site). The reporter assessed this case as non-serious.